APT™ Formulation Combats Multi-Drug Resistant Candida auris: An Emerging Global Healthcare Threat
The Most Effective Topical Treatment to Stop the multi-drug resistant Candida auris spread within hospitals and healthcare facilities, globally
Studies suggest APT™ formulations may provide a safe/easy method to decolonize the skin healthcare workers and patients, thus interrupting skin colonization by the dangerous pathogen, Candida auris.”” Dr. Mahmoud GhannoumROCKWALL, TEXAS, USA, July 25, 2021 /EINPresswire.com/ The CDC recently confirmed outbreaks of Candida auris, a multi-drug resistant fungus, in 2 hospitals located in Collin County Texas (Dallas Metro) and Washington D.C. nursing homes, further demonstrating the need for an effective step in stopping this Superbug fungal infection. There is up to a 60% mortality rate if C. auris enters a patients’ bloodstream. Recent studies conducted at Case Western Reserve University of highly resistant strains of C. auris
A non-prescription intranasal application of APTT3X™ formulation will DECREASE the risk of contracting COVID-19 by 150% . APTT3X™ is a self-administered process of swabbing the lower passages of the nose, represents a scalable preventative solution that could slow the spread of COVID-19 on a global scale” Dr. Ernesto Cesar Pinto Leal Junior, ELJ ConsultancyROCKWALL, TEXAS, UNITED STATES, April 21, 2021 /EINPresswire.com/ The efficacy of the APTT3X™ formulation has been validated in a just-completed clinical trial conducted in Brazil under “Black Flag” conditions. The data makes clear the formulation adds an additional layer of protection and decreases the viral load of exposure. The results of the trial continue to support the clinical field data that has been accumulated over the last 14 months with over 2,500 individuals applying APTT3X™ to decrease their risk of contracting COVID-19 (SARS-CoV-2).
APT™ Formulation Combats Multi-Drug Resistant Candida auris: An Emerging Global Healthcare Threat
Share Article
Candida auris is a multi-drug resistant fungus which can be fatal. There is up to a 55% mortality rate if C. auris enters a patients’ bloodstream. Recent studies conducted at Case Western Reserve University, using highly resistant strains of C. auris provided by the Centers for Disease Control (CDC), have demonstrated that APT™ based antifungal formulations are highly effective in killing this deadly fungus on skin surfaces. The APT™ formulations are the only known effective method that has the potential to remove C. auris from the skin of patients and healthcare workers.